Special Issue

From the Southern Hemisphere: Research on Resistance, Antibiotics and Treatments

Message from the Guest Editors

With the rise in antimicrobial resistance worldwide, many of us have been investigating new ways of overcoming this problem and treating disease. These new technologies may take the form of repurposing antimicrobials, combining antimicrobials for synergy, synthesising new antimicrobials, using phages and parasitic bacteria, as well as understanding the spread of resistance. In this issue we want to highlight new research from the Southern Hemisphere in these, and related areas. Studies can be laboratory based, preclinical or clinical; human or animal based. Manuscripts are particularly welcomed in the following areas:

- New antimicrobials, including antibiotics, disinfectants, metals
- Synthesis of antimicrobials
- New methods of testing antimicrobial activity
- Phages and parasitic bacteria
- Synergism between different types of antimicrobials
- Design and testing of antimicrobial surfaces
- Epidemiology and spread of microbes and resistance traits

Guest Editors

Prof. Dr. Mark Willcox

School of Optometry and Vision Science, University of New South Wales, Sydney, NSW 2052, Australia

Dr. Debarun Dutta

School of Optometry and Vision Science, University of New South Wales, Sydney, NSW 2052, Australia

Deadline for manuscript submissions

closed (31 March 2019)



an Open Access Journal by MDPI

Impact Factor 4.6 CiteScore 8.7 Indexed in PubMed



mdpi.com/si/18358

Antibiotics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
antibiotics@mdpi.com

mdpi.com/journal/ antibiotics





an Open Access Journal by MDPI

Impact Factor 4.6 CiteScore 8.7 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery. use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciples are all key. Antibiotics is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

Editor-in-Chief

Prof. Dr. Nicholas Dixon

School of Chemistry and Molecular Bioscience, University of Wollongong, Wollongong, NSW 2522, Australia

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Infectious Diseases) / CiteScore - Q1 (General Pharmacology, Toxicology and Pharmaceutics)

